Biocept Stock Fundamentals

BIOCDelisted Stock  USD 1.45  0.17  13.28%   
Biocept fundamentals help investors to digest information that contributes to Biocept's financial success or failures. It also enables traders to predict the movement of Biocept Stock. The fundamental analysis module provides a way to measure Biocept's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biocept stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Biocept Company Current Valuation Analysis

Biocept's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Enterprise Value

 = 

Market Cap + Debt

-

Cash

More About Current Valuation | All Equity Analysis

Current Biocept Current Valuation

    
  5.92 M  
Most of Biocept's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biocept is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition

In accordance with the recently published financial statements, Biocept has a Current Valuation of 5.92 M. This is 99.96% lower than that of the Biotechnology sector and 99.92% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.96% higher than that of the company.

Biocept Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Biocept's current stock value. Our valuation model uses many indicators to compare Biocept value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biocept competition to find correlations between indicators driving Biocept's intrinsic value. More Info.
Biocept is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biocept's earnings, one of the primary drivers of an investment's value.

Biocept Current Valuation Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biocept's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biocept could also be used in its relative valuation, which is a method of valuing Biocept by comparing valuation metrics of similar companies.
Biocept is currently under evaluation in current valuation category among its peers.

Biocept Fundamentals

About Biocept Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Biocept's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biocept using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biocept based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. Biocept operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 177 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Other Consideration for investing in Biocept Stock

If you are still planning to invest in Biocept check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biocept's history and understand the potential risks before investing.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Fundamental Analysis
View fundamental data based on most recent published financial statements
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Equity Valuation
Check real value of public entities based on technical and fundamental data